MJC 13
Alternative Names: MJC-13Latest Information Update: 28 Aug 2024
At a glance
- Originator MAIA Biotechnology
- Class Antineoplastics; Small molecules
- Mechanism of Action Tacrolimus binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Breast cancer; Prostate cancer
Highest Development Phases
- No development reported Breast cancer; Prostate cancer
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Breast-cancer in USA (IV, Liquid)
- 28 Aug 2024 No recent reports of development identified for preclinical development in Prostate-cancer in USA (IV, Liquid)
- 24 Feb 2021 MAIA Biotechnology plans to file an IND application for Breast cancer in 2022 (MAIA Biotechnology pipeline, February 2021)